Emerging trends and challenges in AAV manufacturing for gene therapies

Matthew Fuller is the Executive Director at Ultragenyx Pharmaceutical within the Ultragenyx Gene Therapy Research team. He is leading the Pinnacle Producer Cell Line (PCL) and Vector Engineering (VE) teams, both of which perform program and platform research to continually optimize and invest in Ultragenyx’s gene therapy platforms and programs. Specifically, the PCL team focuses on generation, characterization, and improvement of the Pinnacle system to maximize the quality and quantity of rAAV generated. The VE team focuses on optimization of vector construct regulatory elements to modulate and maximize tissue-specific expression and efficacy. Matthew received a PhD in molecular microbiology/virology from the University of Missouri and a MSPH from Tulane University.

Alix Eastham is Senior Manager of the Cell Line Development Team at Ultragenyx Pharmaceutical within the Gene Therapy Research team. The team focuses on developing Pinnacle Producer Cell Lines (PCLs) for the various Ultragenyx gene therapy programs, including the characterization and improvement of the Pinnacle system to maximize the quality and quantity of rAAV generated. Alix received a MSc degree in Molecular Forensic Biology from SUNY Albany.

Ioannis (John) Eugenis is a Product Manager within the ProteinSimple brand of Bio-Techne. He leads the applications strategy of ProteinSimple’s flagship Simple Western product line and Single-Cell Western instruments. John received his PhD in Bioengineering at Stanford University, where he specialized in tissue engineering and regenerative medicine.